Dyfyniad APA

Guo, Z., Lu, X., Yang, F., Qin, L., Yang, N., Wu, J., & Wang, H. (2022). Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: An efficacy and safety analysis. BMC.

Dyfyniad Arddull Chicago

Guo, Zhuifeng, Xuwei Lu, Fan Yang, Liang Qin, Ning Yang, Jiawen Wu, and Hang Wang. Docetaxel Chemotherapy Plus Androgen-deprivation Therapy in High-volume Disease Metastatic Hormone-sensitive Prostate Cancer in Chinese Patients: An Efficacy and Safety Analysis. BMC, 2022.

Dyfyniad MLA

Guo, Zhuifeng, et al. Docetaxel Chemotherapy Plus Androgen-deprivation Therapy in High-volume Disease Metastatic Hormone-sensitive Prostate Cancer in Chinese Patients: An Efficacy and Safety Analysis. BMC, 2022.

Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.